Objective: Determination of psychological problems will shed light on the terms of solution and provide support to patients about these problems will ensure the patients' coherence to the treatment and will enhance the benefits they receive from treatment. In this study, we aimed to determine these psychosocial problems and the interactions with each other in colon cancer patients. Methods: In this study, 105 patients with colorectal cancer were included. The forms consist of sociodemographic features, Hospital Anxiety and Depression Scale, European Organization for Research on Treatment of Cancer Questionnaires Quality of Life-C30 and Golombok-Rust Inventory of Sexual Satisfaction questionnaires. Results: Male patients had significantly higher European Organization for Research on Treatment of Cancer Questionnaires Quality of Life-C30 function scales and global quality-of-life scores than female patients. Golombok-Rust Inventory of Sexual Satisfaction scores of female patients were significantly higher than that of male patients. European Organization for Research on Treatment of Cancer Questionnaires Quality of Life-C30 function scales and global quality-of-life scores of the patients with high depression scores were significantly lower, conversely symptom scale scores of the patients with high depression scores were significantly higher than that of the patients with low depression scores. Patients with low anxiety scores had significantly higher European Organization for Research on Treatment of Cancer Questionnaires Quality of Life-C30 function scales and global quality-of-life scores than the patients with high anxiety scores. Symptom scale scores of the patients with high anxiety scores were significantly higher than that of the patients with low anxiety scores. The scores of Golombok-Rust Inventory of Sexual Satisfaction except premature ejaculation and vaginismus were significantly higher in patients with high anxiety scores and a significant difference was determined in touch, avoidance and anorgasm. Conclusions: This study demonstrates that there is a significant association with anxiety/depression symptoms and quality-of-life scores, sexual dysfunction. Sexual dysfunction is significantly more common in patients with high anxiety and depression scores.
Introduction
Colorectal cancer (CRC) is the third most common cancer both in men and women and the fourth leading cause of cancer-related death worldwide (1) . Mortality rates from CRC have decreased significantly in the last two decades due to the improvements in surgical techniques and adjuvant therapy (2, 3) . Thus, the majority of CRC patients will still remain alive after 5 years and varying population demographics will lead to a rising prevalence of surviving patients with older age (4) . Furthermore, the importance of quality of life (QoL) has become prominent due to the increasing number of surviving patients (5) . Treatment modalities of CRC include surgery, chemotherapy, radiotherapy or both (4) . CRC and treatment strategies may cause long-lasting side effects, known as late effects and may also have negative impact on QoL. Also, the patients with CRC may have long-lasting physical and emotional impairment including lack of energy, sexual dysfunction, anxiety and depression, bowel problems, dyspnea and gastrointestinal problems (6) (7) (8) . Physical and psychological aspects of QoL are important factors in survival and overall patient health (9, 10) . Depression and anxiety are the most important psychopathologic comorbidities of cancer patients (11) . The majority of patients exhibit transient depressive symptoms during the course of their illness, and some of these patients can have more serious depressive syndrome, which can affect their physical, emotional and social functioning (12) . The incidence of major depression in cancer patients has been reported between 3 and 50% according to disease site, stage and the assessment methods used (13) (14) (15) (16) . Depression may result with some clinical and social impairments including treatment efficacy, decision-making, disease recovery and an increase in the risk of mortality, suggesting that effective screening for depression is essential for improving QoL and other outcomes of cancer treatment (17, 18 ). Depression appears to be more common in oropharyngeal, pancreatic, breast and lung cancer patients than the patients with other cancers such as colon, gynecological and lymphoma (19) . However, another study reported that 57% of gastrointestinal cancer patients had high levels of depressive symptoms (20) . It is established that depression may develop in cancer patients due to diagnosis of cancer, long duration of treatment, side effects of treatment, disruption in life and diminished QoL (21, 22) . The CRC survivors tend to have increased health-related QoL in time (23) and longer-lasting depression (24) . Due to evidences in the literature, depression and psychological comorbidity may be considered as predictive of mortality in cancer patients (25, 26) . Some of the important aspects of QoL are sexuality and intimacy (27) and the reasons for sexual dysfunction are both physical and psychological factors. The cancer treatment methods, such as surgery, chemotherapy and radiation therapy, may have direct physiological and psychological impacts on a patient's sexual function or sexuality (28) . Sexuality has been widely studied in prostate, breast and gynecological cancer patients rather than in rectal cancer patients (29) . A wide variety of sexual dysfunctions experienced by CRC survivors were proved by previous studies. A survey of adult CRC patients shows that 18-50% of the patients report some degree of sexual dysfunction after cancer surgery (30) .
The primary aim of the cancer treatment is to improve the survival of the patients. But the physical or psychological problems caused by the disease affect the patients negatively. These psychological problems (anxiety, depression) can cause decrease in the QoL and sexual function disorder. Determination of these problems are thought to shed light on the terms of solution and provide support to patients about these problems will ensure the patients' coherence to the treatment and will enhance the benefits they receive from treatment. In this study, we aimed to determine these psychosocial problems and the interactions with each other in the colon cancer patients.
Patients and methods
One hundred and five patients who were diagnosed with CRC and followed up by Katip Celebi Unıversity and Atatürk Education and Research Hospital, Department of Medical Oncology between June 2012 and April 2014, were involved this study. Informed consent to participate in this study program was obtained from all patients at their initiation of the study. Data were collected using a series of forms to determine the sexual satisfaction, psychological status and QoL of the patients. We performed face-to-face interview with patients who were illiterate or asking for help.
The first form consisted of questions regarding the sociodemographic characteristics of the patients. The second form was the Hospital Anxiety and Depression Scale (HADS). The HAD was developed to define risk and levels of anxiety and depression, as well as to measure their intensity changes for patients in 1983 by Zigmond and Snaith (31) . It is suggested that the introduction of HADS into general hospital practice would facilitate the large task of detection and management of emotional disorder in patients under investigation and treatment in medical and surgical departments. The scale has 14 items, 7 of them (odd numbers) measure anxiety, while the remaining 7 (even numbers) measure depression (31) . All items are rated on a four-point scale, scored from 0 to 3, resulting in maximum subscale scores of 21 and an overall total score ranging from 0 to 42 with higher scores indicating greater levels of depression and anxiety. The validation and reliability study of the scale was developed in Turkey in 1997 by Aydemir. The reliability coefficient of the anxiety and depression HADS subscales for the Turkish patient group was 0.85 and 0.78, respectively (32) .
The third form was the Golombok-Rust Inventory of Sexual Satisfaction (GRISS). The GRISS is a 28-item questionnaire used to evaluate the presence and extent of sexual problems. It has two different versions for males and females. It includes 12 subscales evaluating impotence, premature ejaculation, orgasmic disorder, vaginismus, lack of communication, avoidance in males and females, non-sensuality, insensitivity in males and females and dissatisfaction in males and females. A score of five points or higher in any category indicates sexual dysfunction (33) . In our study, we applied the male and female versions of GRISS. Five subscales are (touch, satisfaction, avoidance, communication and frequency) common in the both versions. We compared these five subscales. The other two subscales (vaginismus and anorgasmi in females; impotence and premature ejaculation in males) were not compared. A validation and reliability study of The Golombok-Rust Inventory in Turkish population was done by Tugȓul et al. (34) .
The fourth form was European Organization for Research on Treatment of Cancer Questionnaires Quality of Life-C30 (EORTCQoL-C30). It consists of 30 items that measures the QoL of cancer patients into three major domains: functional scales, global health/QoL and symptom scales (35) . Functional scales consist of physical (five items), social (two items), emotional (four items), role (two items) and cognitive (two items) items. QoL scale consists of two items and there are nine symptom scales associated with fatigue (three items), nausea and vomiting (two items), pain (two items), dyspnea, insomnia, loss of appetite, diarrhea, financial and constipation (one each item) (36) .
Statistical analysis
All data were analyzed by using SPSS for Windows version 20.0. Descriptive statistics summarized frequencies and percentages for categorical variables, mean and standard deviation for continuous variables. For independent samples, T-tests were used to compare categorical variables. A value of P < 0.05 was considered as significant.
Results
The characteristics of the study population are summarized in Table 1 . The mean age of the patients was 52.87 ± 9.003 years, and 69% of them were males. Of the patients, 92% was primary school graduated, while only 8% were graduated from college. Sixty-seven percent (n = 70) of patients had colon cancer, and 33% (n = 35) had rectal cancer. Of these patients, 54 patients (51%) had local disease, 25 patients (24%) had locally advanced disease and 26 patients (25%) had advanced disease. The majority of the patients (71%) had no stoma. Most of the patients (85%) were married. Sixty-seven percent of the patients were non-smokers and 82% of the patients did not have regular use of alcohol.
In the validation study of HADS scale in Turkey, the cutoff value of depression was 7 and anxiety was 10. In our study, we found that 44% of the patients showed results above the cutoff for depression and 29% of the patients had high anxiety values above the cutoff. Accepted cutoff value of GRISS for Turkish people is 5 and according to this cutoff value it was determined that 16 (15%) patients had problems about avoidance, 42 (40%) had problems about satisfaction, 28 (27%) patients had problems about touch. Thirty-three percent (n = 11) of all these women had problems about vaginismus and 76% (n = 25) had problems about anorgasmi. Seventeen percent (n = 12) of all these men had problems about premature ejaculation and 15% (n = 11) had problems about impotence.
We also assessed the association between EORTC-QoL-C30 scores and anxiety and depression levels of the patients. The EORTC-QoL-C30 function scales and global QoL scores of the depressive patients (HADS D ≥7) were significantly lower than that of the non-depressive patients (HADS D <7). On the other hand, EORTC-QoL-C30 symptom scale scores of the depressive patients were significantly higher than that of the non-depressive patients. Furthermore, there was a statistically significant difference between depressive and non-depressive patients for all function scale scores except role function and other symptom scales except insomnıa, dyspnea and constipation. When both groups (HADS A ≥10 and HADS A <10) were compared, patients with low HADS A scores (HADS A <10) had significantly higher EORTC-QoL-C30 function scales and global QoL scores than the patients with high HADS A scores (HADS A ≥10). EORTC-QoL-C30 symptom scale scores of the patients with high HADS A (HADS A ≥10) were significantly higher than that of the patients with low HADS A scores (HADS A <10). However, there was no statistically significant difference between patients with low HADS A scores and high scores HADS A for some symptom scale scores including dyspnea, constipation, diarrhea and insomnia ( Table 2) .
The scores of GRISS excluding of the premature ejaculation and vaginismus were significantly higher in patients with high anxiety score compared with the patients with low anxiety score and a significant difference was determined in touch, avoidance and anorgasms. Among the patients who had high depression scores, the statistical significance was found only in touch when compared with the patients whose depression scores were low (P = 0.028) ( Table 3) .
When HAD EORTC-QoL-C30 and GRISSscores of patients with CRC were analyzed in terms of their stage, marital status, age, gender and stoma. Our study revealed that gender was strongly associated with HAD, EORTC-QoL-C30 and GRISSscores. The anxiety (P < 0.001) and depressive symptoms were more common in female patients compared with male patients (P = 0.018). Male patients had significantly higher EORTC-QoL-C30 function scales [except emotional functions (EF)] and global QoL scores than female patients. EORTC-QoL-C30 symptom scale scores including fatigue (P = 0.029), pain (P = 0.01), insomnia (P = 0.023) and financial problems (P = 0.02) were significantly higher in female patients compared with men ( Table 4) . GRISSscores of female patients were significantly higher than male patients; the statistical significance was determined in touch (P < 0.001), satisfaction (P = 0.02), avoidance (P < 0.001), communication (P = 0.006) and frequency (P < 0.001) ( Table 5 ). Some functional scales including physical function (P = 0.029) and cognitive function (P = 0.02) were lower in patients with advanced disease compared with other stages. Symptom scales including nausea/vomiting and pain were significantly worse in advanced disease than other stages.
Discussion
In our study, we found that 44% of the patients showed results above the cutoff for depression and 29% of the patients had high anxiety values above the cutoff. Zabora et al. (37) reported that 29-43% of patients with 14 different types of cancer had subclinical or clinical depression and ∼25% of these patients have major depressive disorder. In another study, Nikbakhsh et al. (38) declared that breast and stomach cancer patients in Iran had the highest prevalence of anxiety (46%) and depression (48%). In the Turkish study, Alacacioglu et al. (39) revealed that 23.6% of patients with CRC were depressive.
A recent study of Tsunoda et al. (40) reported that 36.7% of CRC patients were depressive and 7.8% had anxiety according to HADS scale. In the CRC patients, the high prevalence of anxiety and depression can be as a result of the disease itself or the effect of different The bold values are statistically significant.
treatments. Several factors including fatigue, malaise, weight loss and surgical results such as colostomy were found to be significantly associated with anxiety and depression (41) . Additionally, some studies showed significantly higher rates of anxiety and depression in patients with advanced stage disease and receiving chemotherapy (42, 43) . Furthermore, chronic anxiety and depression due to fear of recurrence were reported among cancer patients in remission (44) . Today, in the literature, a wide range of prevalence of depression among cancer patients was demonstrated by a number of studies. Different assessment tools, techniques, populations, disease site and stages can be counted as a reason for this variation.
In our study, EORTC-QoL-C30 function scales ( physical function, role function, cognitive function, EF and social function) and global QoL scores of the depressive patients were significantly lower. Similarly, symptom scale scores of the depressive patients were significantly higher than the non-depressive patients. Patients with low HADS A scores had significantly higher EORTC-QoL-C30 function scales and global QoL scores than the patients with high HADS A scores. Symptom scale scores of the patients with anxiety were significantly higher than the patients without anxiety ( Table 2 ). Bang et al. (45) determined that all variables of EORTC-QoL-C30 scale scores in solid cancer patients were significantly associated with anxiety and depression. Skarstein et al. proved the relationship between the HADS and the QoL-C30 in patients with different cancers. In the same study, the EF aspect of the QoL-C30 was found predominantly to assess anxiety, although depression had a significant effect on most of the aspects of the QoL-C30 (46). Alacacioglu et al. (39) showed that almost all EORTC-QoL-C30 symptoms and functioning scales were associated with anxiety and depression in CRC patients. Frick et al. (11) revealed that anxiety and depression were significantly associated with poor QoL.
In this study, the scores of GRISS excluding of the premature ejaculation and vaginismus were significantly higher in patients with high anxiety scores compared with the patients with low anxiety scores and a significant difference was determined in touch, avoidance and anorgasmi. Among the patients with high depression scores, the statistical significance was found only in touch when compared with the patients with low depression scores. CRC survivors are usually treated with risky methods for sexual problems, including pelvic surgery and radiotherapy, systemic chemotherapy and the presence of a stoma (47) . A survey of the rectal cancer patients shows that 18-50% of adults report some degree of sexual dysfunction after cancer surgery (30) . In addition, depression and anxiety may contribute to sexual problems. Hence, sexual dysfunction is common among survivors and can lead to increased distress. It has a significant negative impact on QoL (48) . In a prospective study of depressive out-patients, the incidence of sexual dysfunction was 14% when relying on spontaneous reporting, but 58% when patients were questioned directly by doctors (49) . In 132 patients with depressive disorders, 72% of patients with unipolar depression and 77% of patients with bipolar depression reported that they have loss of sexual interest, characterized by loss of libido and decreased sexual desire or potency (50) . In another study, negative changes in libido were found significantly more common in depressed patients than controls. But the same study showed no differences in the prevalence of impotence, orgasmic or ejaculatory problems (51) . Anxiety was found several times significantly associated with sexual dysfunction (52) . Anxiety represents the final common pathway by which social, psychological, biological and moral factors converge to impair sexual response. The neurobiological expression of anxiety is not clear, but it mainly occurs with a release of adrenergic substances (epinephrine and norepinephrine). Sympathetic dominance The bold values are statistically significant. is also negatively involved in the arousal and orgasm phases and may interfere with sexual desire (53) . In addition, generalized anxiety disorder was found to be associated with a 2.6-fold greater risk of inhibited orgasm and a 2.1-fold greater risk of inhibited sexual excitement in men and women, and a 2.5-fold greater risk of dyspareunia in women (54) . Moreover, women with anxiety of a greater severity have decreased sexual arousal (55) .
When HAD scores, EORTC-QoL-C30 and GRISSscores of patients with CRC were analyzed in terms of their disease stage, marital status, age, gender and stoma, our study revealed that gender was strongly associated with these scores. The anxiety (P < 0.001) and depressive symptoms were more common in female patients compared with male patients (P = 0.018). Generally, the preponderance gender who reports depressive symptoms is female. Gender differences in the prevalence or severity of depression in cancer patients were evaluated by a few studies. Although some studies found no gender differences among depression rates (56, 57) , the other studies reported that women have higher prevalence rates of depression (14, 58) . The oncology outpatients who were 50 years old or >50 years and were receiving active treatment for cancer, were evaluated for gender differences in the severity of depression by Given et al.. Using the Center for Epidemiological Studies-Depression scale, they found a positive interaction between age and gender on the level of depression. For men, for each increased 1 year of age, a decrease of 0.33 units in depression score was demonstrated; whereas for women, for each increased 1 year of age, an increase of 0.16 units in depression score was found (59) .
In our study, male patients had significantly higher EORTC-QLQC30 function scales (with the exception of EF) and higher globalQoL scores than female patients. EORTC-QLQC30 symptom scale scores including fatigue (P = 0.029), pain (P = 0.01), insomnia (P = 0.023) and financial problems (P = 0.020) were significantly higher in female patients compared with men. Despite reporting no gender differences for QoL in some studies, some specific problems like sexual functioning in men or physical problems and pains in women are confounding factors for these studies (60). Mosconi et al. (61) reported that male patients had better outcomes for physical function, emotional function, role performance, general health/QoL and for the symptoms of fatigue and pain. Similar to this study, Schmidt et al. compared the QoL of 264 men and 255 women with rectal cancer and reported that females had a lower QoL for physical function and general health status than men (62) .
In our study, GRISS scores of female patients were significantly higher than the male patients. The statistical significance was determined for touch (P < 0.001), satisfaction (P = 0.020), avoidance (P < 0.001), communication (P = 0.006) and frequency (P < 0.001). Marijnen et al. reported significant declines in sexual activity and significantly worse sexual function over the course of the study on both men and women. In the same study, receiving pre-operative radiotherapy was found to be significantly associated with these negative changes (63). Laumann et al. (64) reported that sexual dysfunction in the general population was found to be more frequent in women (43%) than in men (31%). According to the previous studies, 30-40% of survivors may discontinue sexual activity and high percentages ranging from 23 to 69% of men and from 19 to 62% of women may experience new sexual dysfunctions (65) . The knowledge about sexual problems of female patients after CRC treatment is very few due to the fact that elder female survivors are often reluctant to complete questionnaires on sexuality (66) . Many postmenopausal women do not have a partner or their partner has a disease or erectile dysfunction. Hence, the elder female patients are not sexually active during cancer diagnosis. After CRC treatment, women are more likely to give up sexual activity than men (65, 67) . Female patients who underwent pelvic radiation also have significant sexual problems related to vaginal agglutination, pronounced vaginal fibrosis, stenosis and loss of lubrication. Women, who has treatment related menopause, often find themselves in a vexing vicious circle. When they lose interest in sexual activity due to pain, consequently, vaginal atrophy and loss of desire increase by the time passes (68, 69) . Other common reasons for sexual problem are worries about the surgical impact on the body and concerns about body image (70) .
Limited number of patients, different follow-up intervals and as applied crosssectionally were major limitations of our study. Additionally, information regarding sexual (dys)function before diagnosis/treatment of cancer was not known, which limits the determination of the effect of a cancer diagnosis and treatment on functioning or being able to correct for baseline functioning.
This study demonstrates that there is a significant association between anxiety/depression symptoms, QoL scores and sexual dysfunction. Sexual dysfunction is significantly more common among cancer patients with high HAD A/D scores and female gender. Thus, we found that anxiety and depression levels were strongly associated with the poor QoL and sexual dysfunction in Turkish CRC patients.
